|Active Ingredient (Generic Name):|
Eyelashes Growth, Glaucoma, Ocular Hypertension
Sun Pharmaceutical Industries Ltd
6 To 15 days
Careprost Eye Drop is by definition similar to prostaglandin. It is a medicine used topically (in the form of eye drops) to control the progression of glaucoma and ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of fluid from the eyes. It is known to be used to extend eyelashes. The FDA approved this method of administration in December 2008. During the period 2008-2011, it is noticed that Careprost Eye Drop has the ability to reduce fat tissue.
How it works
Your eyes contain a clear, clean fluid that keeps within the eye. The fluid is always depleted from the eye, and the new fluid is made to replace it. On the off chance that the liquid can’t be depleted rapidly enough, the pressure inside the eye increase. This medication works by expanding the amount of liquid that is depleted. It diminishes the pressure in your eye. If the increased pressure is not reduced, it can lead to a condition called glaucoma and possibly to visual complication.
The essence of activity by which Careprost brings down intraocular pressure in people is the expansion flow of the eye fluid through the trabecular gland and the improvement of uveoscleral flow. The diminishing intraocular pressure starts roughly 4 hours after the primal administration of the medication, and the biggest effect comes around 8 to 12 hours after application.
The length of the drug effect is kept up for somewhere around 24 hours.
Careprost is a potent remedy for reducing eye pressure. It is an engineered prostamide, fundamentally like prostaglandin F2α (PGF2α), which does not work through known prostaglandin receptors. Careprost specifically impersonates the impacts of newfound biosynthesized substances known as prostamides. Careprost selectively imitates the effects of newly discovered biosynthesized substances known as prostamides. However, the structure of prostamides receptors has not yet been identified.
Dosage and application
The standard dose is one drop in the affected eye or eyes once a day, applied in the evening. Dose once a day should not be exceeded because the frequent application can reduce the effect of lowering intraocular pressure. Careprost passes excellently through cornea and sclera.
Before starting the treatment, it is necessary to inform the patient about the possibility of growth of eyelashes, darkening of the skin of the eyelids, and enhanced pigmentation of the iris, since these changes have been observed during the treatment with Careprost. Some of these changes can be permanent and can lead to differences in the eyes if only one eye is treated. Increased pigmentation of an iris is probably lasting. The long-term impacts of iris pigmentation are not known. The change in the iris color seen in the ophthalmic use of Careprost can be observed for several months or years. Normally, dark-colored pigmentation around the pupil stretches out concentrically to the outskirts of the iris and the whole iris or parts turn out to be color brown.
There is a possibility of hair growth in the area where the solution of the Careprost product comes into contact with the skin surface on several occasions. So, it is important that Careprost is applied according to the instructions and to avoid leakage on the face or other parts of the skin.
The side effects of Careprost are numerous but in a very low percentage compared to other drugs of this type.
- Conjunctival hyperemia
- Keratitis, eye irritation, erythema of the eyelids, asthenia, blurred vision, conjunctival disorder, conjunctival edema, hyperpigmentation of iris, edema of the eyelid.
- Macular edema, periorbital and eyelid changes including deepening of the eyelid sulcus, dry eye.
- Asthma, exacerbation of asthma, exacerbation of HOBP, dyspnea
- Hyperpigmentation of the skin, hypertrichosis
- Dry skin, itching
- Common irritation at the site of application
- Immune system disorders, hypersensitivity reaction including signs and symptoms of eye allergy and allergic dermatitis.
No cases of overdosage with Careprost have been reported and it is unlikely that an overdose will occur after ocular administration.
If overdose happens, treatment needs to be symptomatic. If any of these undesirable effects is revealed go to your doctor as soon as possible.
Drug Careprost is contraindicated in patients who have had a suspected adverse reaction to benzalkonium chloride, which has led to the discontinuation of therapy.
Should I use Careprost while I wear contact lenses?
Drug Careprost contains benzalkonium chloride which can be absorbed by soft contact lenses. Also, eye irritation and discolouration of soft contact lenses may occur due to the presence of benzalkonium chloride. Contact lenses should be removed prior to administration and can be restored after 15 minutes of administration.
Should I drive while using Careprost?
Drug Careprost has a negligible impact on the ability to drive and handle machines.
As with other therapies related to the treatment of eye disorders, if there is a transient blurred vision in the application of the drug, it is necessary for the patient to wait for driving or operating the machines until the vision is cleared.
For whom Careprost is dangerous to use?
Careprost medications should not be used by people who are allergic to the main ingredients of the drug, who have any kidney disease or liver disease, and pregnant or breastfeeding women.
Can Careprost be used to increase eyelashes?
It has been proven in numerous studies that Careprost, in addition to being used to treat glaucoma and elevated intraocular pressure of unknown etiology, can also be used in the cosmetic industry as an addition to nutrition and the growth of eyelashes.
Can I use Careprost package with other people in my environment?
Careprost should not be used with other people because there is a possibility of contamination of the product. There are reports of bacterial keratitis associated with the use of packing by several persons at once. These packs were accidentally contaminated by patients who, in most cases, had eye disease at the same time. Patients with impaired epithelium on the surface of the eye are at greater risk of developing bacterial keratitis.